| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Clofibric acid (BRN-1874067; CCRIS 9254; BRN1874067; NSC 1149; NSC1149; Chlorofibrinic acid), the active metabolite of clofibrate, etofibrate and theofibrate (the lipid-lowering drugs), is a potent PPARα agonist and anti-hyperlipidemic agent.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
J Biol Chem.1992 Sep 25;267(27):19051-3;Biochem Pharmacol.1993 May 25;45(10):2045-53.
|
| Molecular Formula |
C10H11CLO3
|
|
|---|---|---|
| Molecular Weight |
214.65
|
|
| CAS # |
882-09-7
|
|
| Related CAS # |
Clofibric acid-d4;1184991-14-7
|
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])C=1[H])OC(C(=O)O[H])(C([H])([H])[H])C([H])([H])[H]
|
|
| InChi Key |
TXCGAZHTZHNUAI-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)
|
|
| Chemical Name |
2-(4-chlorophenoxy)-2-methylpropanoic acid
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6587 mL | 23.2937 mL | 46.5875 mL | |
| 5 mM | 0.9317 mL | 4.6587 mL | 9.3175 mL | |
| 10 mM | 0.4659 mL | 2.3294 mL | 4.6587 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01527318 | Completed | Drug: Fibrate treatment | Neutral Lipid Storage Disease | Maastricht University Medical Center | August 2011 | Phase 4 |
| NCT03586674 | Completed | Drug: Lipanthyl Drug: Ursogal |
Chronic Cholestasis | Hoda A. Atta | November 1, 2017 | Phase 2 |
| NCT00243672 | Withdrawn | Drug: Atorvastatin Drug: Gemfibrozil |
Atherosclerosis | University Hospital Muenster | October 2005 | Phase 4 |
| NCT00491400 | Terminated Has Results | Drug: Fenofibrate Drug: Atorvastatin |
Diabetes Mellitus Metabolic Syndrome |
Boston University | September 2005 | Not Applicable |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
